CoChat

Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature

Open access

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index; 18 of the 38 sources its claims cite were checked for support.

Abstract

Rationale Methamphetamine use and related harms have risen at alarming rates. While several psychosocial and pharmacologic interventions have been described in the literature, there is uncertainty regarding the best approach for the management of methamphetamine use disorder (MUD) and problematic methamphetamine use (PMU). We conducted a scoping review of recent systematic reviews (SR), clinical practice guidelines (CPG), and primary controlled studies of psychosocial and pharmacologic treatments for MUD/PMU. Methods Guided by an a priori protocol, electronic database search updates (e.g., MEDLINE, Embase) were performed in February 2022. Screening was performed following a two-stage process, leveraging artificial intelligence to increase efficiency of title and abstract screening. Studies involving individuals who use methamphetamine, including key subgroups (e.g. those with mental health comorbidities; adolescents/youths; gay, bisexual, and other men who have sex with men) were sought. We examined evidence related to methamphetamine use, relapse, use of other substances, risk behaviors, mental health, harms, and retention. Figures, tables and descriptive synthesis were used to present findings from the identified literature. Results We identified 2 SRs, one CPG, and 54 primary studies reported in 69 publications that met our eligibility criteria. Amongst SRs, one concluded that psychostimulants had no effect on methamphetamine abstinence or treatment retention while the other reported no effect of topiramate on cravings. The CPG strongly recommended psychosocial interventions as well as self-help and family support groups for post-acute management of methamphetamine-related disorders. Amongst primary studies, many interventions were assessed by only single studies; contingency management was the therapy most commonly associated with evidence of potential effectiveness, while bupropion and modafinil were analogously the most common pharmacologic interventions. Nearly all interventions showed signs of potential benefit on at least one methamphetamine-related outcome measure. Discussion This scoping review provides an overview of available interventions for the treatment of MUD/PMU. As most interventions were reported by a single study, the effectiveness of available interventions remains uncertain. Primary studies with longer durations of treatment and follow-up, larger sample sizes, and of special populations are required for conclusive recommendations of best approaches for the treatment of MUD/PMU. Copyright: © 2023 Hersi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Overview

CoChat Summary

## TL;DR

This scoping review mapped recent systematic reviews, one clinical practice guideline, and primary controlled studies of psychosocial and pharmacologic interventions for methamphetamine use disorder/problematic methamphetamine use. The evidence base was sparse and heterogeneous, so the authors conclude that the effectiveness of most interventions remains uncertain.

## Key findings

  • The review identified 2 systematic reviews, 1 clinical practice guideline, and 54 primary studies in 69 publications that met eligibility criteria.
  • In the primary-study evidence, 952 treatment-effect estimates were charted; the most commonly reported outcomes were retention/dropout (45 studies, 249 estimates), methamphetamine use and abstinence (32 studies, 253 estimates), and change in methamphetamine use (34 studies, 139 estimates).
  • Contingency management was the psychosocial therapy most commonly associated with evidence of potential effectiveness, while bupropion and modafinil were the most common pharmacologic interventions; the paper also notes that nearly all interventions showed signs of potential benefit on at least one methamphetamine-related outcome measure.
  • The included guideline strongly recommended psychosocial interventions, including self-help and family support groups, and also recommended disease-specific evidence-based treatment and psychoeducation for co-occurring mental health and substance use conditions.

## Methods

  • Design: Scoping review, guided by an a priori protocol and reported using PRISMA-ScR; the protocol was published and registered on the Open Science Framework.
  • Data/sample: Recent SRs and CPGs published 2015 or later, plus primary controlled studies in people who use methamphetamine, including key subgroups (e.g., mental health comorbidities, adolescents/youth, gbMSM, pregnant people, correctional populations); searches were updated in February 2022.
  • Main analysis: Study selection and extraction were done with two-stage screening; SRs/CPGs were quality appraised with AMSTAR-2 and AGREE-2; primary-study findings were synthesized with vote counting based on direction of effect and descriptive/narrative summaries, and the feasibility of network meta-analysis was assessed.

## Limitations

  • The paper states that, consistent with scoping review methods, it used a high-level synthesis that often required consolidating similar outcomes despite differences in how they were defined or measured.
  • The vote-counting approach did not account for effect size, statistical significance, or sample-size differences across studies, which the authors say limits the conclusions that can be drawn.
  • The evidence base was sparse and heterogeneous, with many interventions evaluated in only a single study; additionally, the review was limited to English and French publications, so the paper notes it is unknown whether excluded-language studies would have met eligibility criteria.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0292745

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 PRISMA diagrams.
Fig 1 PRISMA diagrams.CC BY · PubMed Central
Fig 2 Summary of outcomes reported in primary studies. Methamphetamine use, abstinence: 195 of 253 estimates included in synthesis, Change in methamphetamine use: 90 of 139 estimates included in synthesis.
Fig 2 Summary of outcomes reported in primary studies. Methamphetamine use, abstinence: 195 of 253 estimates included in synthesis, Change in methamphetamine use: 90 of 139 estimates included in synthesis.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 11 Not checked · 62 Own results and interpretations

24 more claims

Create a free account to see all 84 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 36
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Citations

Cites

Show all 103 references

Research works printed but not linked: 7

  1. M Kuo, 2012, Pilot project report: survey on drug use among harm reduction clients, British Columbia Center for Disease Control
  2. National Institute on Drug Abuse, 2023, What is the scope of methamphetamine use in the United States?
  3. NIH Research Matters, 2021, Trends in U.S. methamphetamine use and associated deaths
  4. European Monitoring Centre for Drugs and Drug Addiction, 2022, Signals of spreading methamphetamine use in Europe
  5. JPT Higgins, 2011, Part 2: General methods for Cochrane reviews
  6. WD Braunwarth, 2016, S3 practice guideline methamphetamine-related disorders
  7. Grigg J, Manning V, Arunogiri S et al. Methamphetamine Treatment Guidelines: Practice Guidelines for Health Professionals (2nd edition). Australia; 2018. Available: https://www.turningpoint.org.au/sites/default/files/2019-05/Turning-Point-Methamphetamine-Treatment-Guidelines.pdf

Cited by

See all 13

Metadata

Authors
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., MacPherson, P., Sproule, B., Flores-Aranda, J., Dickey, C., & Hutton, B.
Affiliations
  • Ottawa Hospital Research Institute (CA)
  • University of Ottawa (CA)
  • McGill University (CA)
  • Centre for Addiction and Mental Health (CA)
  • Université du Québec à Montréal (CA)
  • Western University (CA)
Corresponding author
Hutton, Brian
Venue
PLoS ONE
Published
2023-10-11
Volume
18
Issue
10
Pages
e0292745
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4387526402
Cited by
13
References
101
Citations by year
2026: 5 · 2025: 6 · 2024: 2
FWCI
0.51
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
methamphetamine dependence, psychosocial interventions, pharmacological interventions, contingency management, topiramate, bupropion, modafinil, psychostimulants, treatment retention, relapse, substance use comorbidity, adolescents and youth, men who have sex with men, family support groups, self-help
MeSH terms
Sexual and Gender Minorities, Adolescent, Central Nervous System Stimulants, Artificial Intelligence, Humans, Male, Methamphetamine, Homosexuality, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature. https://app.cochat.ai/papers/10.1371/journal.pone.0292745
The paper
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., MacPherson, P., Sproule, B., Flores-Aranda, J., Dickey, C., & Hutton, B. (2023). Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature. PLoS ONE. https://doi.org/10.1371/journal.pone.0292745

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.